Genome-wide association analysis identifies a meningioma risk locus at 11p15.5. Read more about Genome-wide association analysis identifies a meningioma risk locus at 11p15.5.
Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Read more about Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma.
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Read more about Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Read more about Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
Temozolomide-associated hypermutation in gliomas. Read more about Temozolomide-associated hypermutation in gliomas.
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Read more about Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.
Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Read more about Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.
The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors. Read more about The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors.
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Read more about Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma. Read more about A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma.
